Dasiglucagon

Zealand Pharma Announces Full Year Results for 2022

Retrieved on: 
Thursday, March 2, 2023
DREAM, Boehringer Ingelheim, CHI, Congenital hyperinsulinism, Safety, SAD, Congress, Insulin, FDA, European Medicines Agency, Novo Nordisk, Short bowel syndrome, MAA, NDA, Human, Patient, BMI, MAD, Marketing, GIP, PIN, S&M, Webcast, G&A, Dasiglucagon, Obesity, Glucagon, Q&A, EASE, EMA, SBS, Bionics, Cryptocurrency, Pharmaceutical industry, Alexion, DKK

Boehringer Ingelheim is planning to share the results of the trial with the scientific community in the coming months.

Key Points: 
  • Boehringer Ingelheim is planning to share the results of the trial with the scientific community in the coming months.
  • Separately, in the second half of 2023, Zealand expects to initiate a 13-week dose titration trial in people with obesity.
  • In the second half of the year, Zealand expects to report topline results from the ongoing 6-week multiple ascending dose (MAD) trial (NCT05613387) and initiate a 16-week dose titration trial.
  • Zealand anticipates advancing ZP6590 into a Phase 1 SAD trial in healthy volunteers in the second half of 2023.

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting

Retrieved on: 
Monday, September 19, 2022
GIR, Time, Safety, Hypoglycemia, Endocrine Society, IV, Child, Hospital, Part, European Society of Gynaecological Oncology, Dasiglucagon, Philadelphia, Glycemia, Patient, CHI, 2021 Essex County Council election, Pancreatectomy, CGM, Diabetes, Congenital hyperinsulinism, Part Two, ESPE, DK, Disease, Medical imaging, Pharmaceutical industry, Vaccine, Medical device, Zealand Pharma, Endocrinology

Though congenital hyperinsulinism is an incredibly challenging disease to manage, the efficacy and safety of dasiglucagon observed in this Phase 3 trial, support its potential as a new treatment option for children with CHI.

Key Points: 
  • Though congenital hyperinsulinism is an incredibly challenging disease to manage, the efficacy and safety of dasiglucagon observed in this Phase 3 trial, support its potential as a new treatment option for children with CHI.
  • We are very pleased to present the compelling results from the Phase 3 study of dasiglucagon in newborns and infants up to 12 months of age at ESPE 2022.
  • This study deepens our understanding of dasiglucagons potential as an innovative treatment for CHI patients, said David Kendall, M.D., Chief Medical Officer of Zealand Pharma.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines.

Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)  

Retrieved on: 
Thursday, May 19, 2022
Royal commission, Congenital hyperinsulinism, Medicine, Private Securities Litigation Reform Act, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, European Commission, Nasdaq, Patient, Hypoglycemia, SOC, Dasiglucagon, DK, IV, COVID-19, Failure, Marketing, Research, FDA, Intellectual property, Program, DEKA, Standard of care, Advertising, NDA, Boehringer Ingelheim, Pancreatectomy, AstraZeneca, Zealand Pharma, Medical device, Pharmaceutical industry, CHI

20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced positive top-line results from its second Phase 3 clinical trial of dasiglucagon in pediatric patients with congenital hyperinsulinism (CHI).

Key Points: 
  • 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced positive top-line results from its second Phase 3 clinical trial of dasiglucagon in pediatric patients with congenital hyperinsulinism (CHI).
  • The Phase 3 program for dasiglucagon constitutes the largest clinical development program ever conducted in CHI.
  • In total, 42 of 44 participants enrolled across the dasiglucagon CHI Phase 3 clinical programs continued into the ongoing safety extension trial.
  • We are extremely pleased with the top-line results from our second Phase 3 study of dasiglucagon for the treatment of infants with CHI.